Want to see HK:0314 full AI Analyst Report?
Top Page
Sipai Health Technology Co., Ltd.
(0314)
Select Model
Select Model
Rating:50Neutral
Price Target:
HK$1.50
▼(-39.52% Downside)
Action:Reiterated
Date:09/06/26
The score is held back primarily by weak financial performance—continued losses and a steep 2025 revenue contraction—despite some improving signals (better gross margin, lower leverage, and modestly positive operating cash flow in 2025). Technicals provide partial support with improving short-to-medium term momentum, but valuation remains challenged due to negative earnings and no dividend yield provided.
Positive Factors
Manageable leverage
Recent leverage is low relative to equity, while positive and sizable equity provides a stronger capital base. This reduces near-term balance-sheet pressure and preserves more flexibility to fund operations or respond to changing conditions.
Negative Factors
Severe revenue contraction
The sharp revenue contraction directly weakens scale, operating leverage, and the company’s ability to absorb fixed costs. Continued top-line pressure could offset margin improvements and delay a sustainable return to profitability over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable leverage
Recent leverage is low relative to equity, while positive and sizable equity provides a stronger capital base. This reduces near-term balance-sheet pressure and preserves more flexibility to fund operations or respond to changing conditions.
Read all positive factors
Sipai Health Technology Co., Ltd. (0314) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$891.39M
Dividend YieldN/A
Average Volume (3M)849.33K
Price to Earnings (P/E)―
Beta (1Y)0.37
Revenue Growth-52.19%
EPS Growth97.51%
CountryHK
Employees3,131
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)-0.50
Shares Outstanding765,783,500
10 Day Avg. Volume734,880
30 Day Avg. Volume849,332
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)1.44
Price to Sales (P/S)0.67
P/FCF Ratio10.60K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.03
Revenue Forecast (FY)HK$1.71B
Sipai Health Technology Co., Ltd. Business Overview & Revenue Model
Company Description
Sipai Health Technology Co., Ltd. is a Chinese enterprise specializing in medical technology and health management. Its business operations are diversified across three primary divisions: Specialty Pharmacy, Physician Research Assistance, and Heal...
Sipai Health Technology Co., Ltd. Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
35
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.43B | 2.02B | 4.57B | 4.71B | 4.12B | 3.47B |
| Gross Profit | 332.69M | 277.08M | 386.43M | 414.70M | 337.35M | 281.06M |
| EBITDA | -227.95M | -75.52M | -259.52M | -226.10M | -1.35B | -652.40M |
| Net Income | -317.52M | -121.05M | -323.74M | -255.77M | -1.37B | -3.74B |
Balance Sheet | ||||||
| Total Assets | 1.83B | 1.60B | 2.27B | 2.82B | 2.93B | 2.89B |
| Cash, Cash Equivalents and Short-Term Investments | 597.85M | 665.35M | 919.77M | 1.13B | 1.53B | 1.61B |
| Total Debt | 24.70M | 22.59M | 66.49M | 67.56M | 67.76M | 7.52B |
| Total Liabilities | 876.01M | 703.20M | 1.06B | 1.18B | 1.10B | 8.32B |
| Stockholders Equity | 995.88M | 936.71M | 1.23B | 1.62B | 1.84B | -5.43B |
Cash Flow | ||||||
| Free Cash Flow | -124.99M | 127.00K | -67.91M | -139.24M | -193.87M | -643.33M |
| Operating Cash Flow | -121.64M | 6.36M | -59.45M | -133.50M | -182.07M | -621.92M |
| Investing Cash Flow | 374.57M | 229.67M | -622.00K | -720.81M | 1.03B | -1.02B |
| Financing Cash Flow | -269.76M | -218.77M | -184.06M | -120.55M | 81.69M | 559.29M |
Sipai Health Technology Co., Ltd. Technical Analysis
Positive
2.48
Price Trends
1.45
Positive
1.39
Positive
1.90
Negative
Market Momentum
0.04
Positive
60.72
Neutral
84.33
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0314, the sentiment is Positive. The current price of 2.48 is above the 20-day moving average (MA) of 1.54, above the 50-day MA of 1.45, and above the 200-day MA of 1.90, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 60.72 is Neutral, neither overbought nor oversold. The STOCH value of 84.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0314.
Sipai Health Technology Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | HK$976.17M | -13.80 | -3.87% | ― | 8.73% | 80.38% | |
53 Neutral | HK$578.75M | 10.62 | 28.00% | ― | 91.32% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$841.88M | -46.91 | -5.98% | ― | -3.77% | 73.89% | |
50 Neutral | HK$891.39M | -11.56 | -7.38% | ― | -52.19% | 97.51% | |
50 Neutral | HK$539.27M | -1.51 | -25.36% | 1.47% | -8.94% | -140.82% | |
49 Neutral | HK$828.11M | -10.36 | -5.98% | ― | 10.67% | 57.27% |
* Healthcare Sector Average
HK:0314
Sipai Health Technology Co., Ltd.
1.59
-2.28
-58.91%
HK:9886
Dingdang Health Technology Group Ltd.
0.80
-0.08
-9.66%
HK:2138
EC Healthcare
0.51
-0.30
-37.04%
HK:2159
Mediwelcome Healthcare Management & Technology Inc.
1.72
0.26
17.81%
HK:2251
Beijing Airdoc Technology Co. Ltd. Class H
8.50
-6.63
-43.82%
HK:9686
NEUSOFT XIKANG HOLDINGS INC.
1.00
0.00
0.00%
Sipai Health Technology Co., Ltd. Corporate Events
Sipai Health Redeems RMB50 Million Wealth Product to Fund Acquisition
Aug 27, 2026
Sipai Health Technology’s subsidiary, Sipai Healthcare Investment, has redeemed a principal‑guaranteed cash management wealth management product from Industrial Bank, withdrawing RMB50 million on August 27, 2026, after subscribing on J...
Sipai Health Swings to Profit Despite Sharp Interim Revenue Decline
Aug 20, 2026
Sipai Health Technology Co., Ltd. reported a sharp drop in interim revenue for the six months ended June 30, 2026, with total revenue falling 39.6% year-on-year to RMB739.9 million. The decline was driven mainly by its specialty pharmacy business,...
Sipai Health Schedules Board Meeting to Approve Interim Results and Dividend
Aug 10, 2026
Sipai Health Technology Co., Ltd. has scheduled a board meeting for August 20, 2026 to review and approve the unaudited interim results for the six months ended June 30, 2026. The board will also consider whether to declare an interim dividend, a ...
Sipai Health Technology Signals Profit Turnaround on Core Business Growth
Aug 4, 2026
Sipai Health Technology Co., Ltd., a Cayman Islands‑incorporated company listed in Hong Kong, focuses on healthcare‑related corporate insurance services and physician research assistance. Its strategy centers on expanding higher‑...
Sipai Health Technology Discloses RMB80 Million Industrial Bank Wealth Product Subscriptions
Jul 31, 2026
Sipai Health Technology, via its subsidiary Sipai Healthcare Investment, has subscribed to cash and fixed-income wealth management products offered by Industrial Bank, deploying a total outstanding principal of RMB80,000,000. These products invest...
Sipai Health Executives Boost Stakes as Company Ramps Up Share Buybacks
Jul 15, 2026
Sipai Health Technology Co., Ltd. has announced that executive directors Ma Xuguang and Li Ji have each acquired 3,640,000 shares on July 15, 2026, at HK$1.40 per share, lifting their holdings to about 8.34% and 6.00% of issued shares respectively...
Sipai Health Technology Shareholders Approve All AGM Resolutions
Jun 18, 2026
Sipai Health Technology Co., Ltd. reported that all resolutions at its June 18, 2026 annual general meeting in Shanghai were approved by shareholders via poll, including adoption of the 2025 audited financial statements. Shareholders also supporte...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.